<?xml version="1.0" encoding="UTF-8"?>
<ref id="cit0038">
 <label>38.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Zhu</surname>
    <given-names>FC</given-names>
   </name>, 
   <name name-style="western">
    <surname>Li</surname>
    <given-names>YH</given-names>
   </name>, 
   <name name-style="western">
    <surname>Guan</surname>
    <given-names>XH</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hou</surname>
    <given-names>L-H</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wang</surname>
    <given-names>W-J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Li</surname>
    <given-names>J-X</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wu</surname>
    <given-names>S-P</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wang</surname>
    <given-names>B-S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wang</surname>
    <given-names>Z</given-names>
   </name>, 
   <name name-style="western">
    <surname>Wang</surname>
    <given-names>L</given-names>
   </name>, et al
  </person-group>
  <article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title>. 
  <source>Lancet</source>. 
  <year>2020</year>;
  <volume>395</volume>(
  <issue>10240</issue>):
  <fpage>1845</fpage>â€“
  <lpage>54</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id>.
  <pub-id pub-id-type="pmid">32450106</pub-id>
 </mixed-citation>
</ref>
